Leishmaniasis: Prevention, parasite detection and treatment

Current Medicinal Chemistry

Volumn 19, Issue 10, 2012, Pages 1443-1474

  Kobets, T ^a   Grekov, I ^a   Lipoldova M ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Animal model; Cutaneous and mucocutaneous leishmaniasis; Estimation of pathogen load; Kala azar; Preventive medicine; Therapy of visceral; Tropical disease

Indexed keywords

ALLOPURINOL; AMINOLEVULINIC ACID; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; AZITHROMYCIN; CRYSTAL VIOLET; CYANINE DYE; DAPSONE; DNA VACCINE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LEISHMANIA VACCINE; LEISHMUNE; LEISHVACCIN; LICOCHALCONE A; LIVE VACCINE; MEGLUMINE ANTIMONATE; METHYLENE BLUE; MILTEFOSINE; MPL SE; PAROMOMYCIN; PENTAMIDINE; PEPTIDE VACCINE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYRIN; PROTOPORPHYRIN; RIFAMPICIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE CANILEISH;

AGRANULOCYTOSIS; ANTIPROTOZOAL ACTIVITY; ARTHRALGIA; BACKACHE; CARDIOTOXICITY; CHILL; CHOLESTASIS; DIABETES MELLITUS; DIARRHEA; DNA DETERMINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLUORESCENCE MICROSCOPY; GASTROINTESTINAL SYMPTOM; GENOME ANALYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; HYPOTHYROIDISM; IMMUNODETECTION; INFECTION CONTROL; LEISHMANIA; LEISHMANIASIS; LIVER DISEASE; METHEMOGLOBINEMIA; MORTALITY; MYALGIA; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PARASITE IDENTIFICATION; PARASITE VECTOR; PHOTODYNAMIC THERAPY; PNEUMONIA; QUANTITATIVE ANALYSIS; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RIGOR; SEQUENCE ANALYSIS; SKIN LEISHMANIASIS; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; VACCINATION; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIPROTOZOAL AGENTS; DNA, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEISHMANIA; LEISHMANIASIS; MICROSCOPY; PROTOZOAN VACCINES; SKIN TESTS; VACCINES, DNA;

EID: 84858773500     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799828300     Document Type: Review

References (336)

1. Herwaldt, B.L. Leishmaniasis. Lancet, 1999, 354(9185), 1191-1199. (Pubitemid 29460458)
2. Pavli, A.; Maltezou, H.C. Leishmaniasis, an emerging infection in travelers. Int. J. Infect. Dis., 2010, 14(12), e1032-e1039.
3. Bates, P.A. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int. J. Parasitol., 2007, 37(10), 1097-1106. (Pubitemid 47042030)
4. Lipoldová, M.; Demant, P. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat. Rev. Genet., 2006, 7(4), 294-305.
5. Terrazas, C.A.; Terrazas, L.I.; Gomez-Garcia, L. Modulation of dendritic cell responses by parasites: a common strategy to survive. J. Biomed. Biotechnol., 2010, 2010, 357106.
6. Bogdan, C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell. Microbiol., 2008, 10(6), 1221-1234. (Pubitemid 351663916)
7. Tuon, F.F.; Neto, V.A.; Amato, V.S. Leishmania: origin, evolution and future since the Precambrian. FEMS Immunol Med. Microbiol., 2008, 54(2), 158-166.
8. Zink, A.R.; Spigelman, M.; Schraut, B.; Greenblatt, C.L.; Nerlich, A.G.; Donoghue, H.D. Leishmaniasis in ancient Egypt and Upper Nubia. Emerg. Infect. Dis., 2006, 12(10), 1616-1617. (Pubitemid 44570920)
9. Costa, M.A.; Matheson, C.; Iachetta, L.; Llagostera, A.; Appenzeller, O. Ancient leishmaniasis in a highland desert of Northern Chile. PLoS One, 2009, 4(9), e6983.
10. Cunningham, D. D. On the presence of peculiar parasitic organisms in the tissue of a specimen of Delhi boil. Scientific memoirs by officers of the Medical and Sanitary Departments of the Government of India; Government printing: Calcutta, India, 1885; 1, 21-31.
11. Borovsky, P.F. [On Sart Sore.] Voenno-Medicinskij Zurnal (Military Medical Journal), 1898, 195(11), 925-941.
12. Leishman, W.B. On the possibility of the occurence of trypanosomiasis in India. Brit. Med. J., 1903, 1,1252-1254.
13. Donovan, C. Memoranda: on the possibility of the occurence of trypanomiasis in India. Brit. Med. J., 1903, 2, 79.
14. Martsinovsky, E.I. [The etiology of oriental sore.] DSc. Thesis, Moscow, 1909.
15. Dujardin, J.C.; Campino, L.; Canavate, C.; Dedet, J.P.; Gradoni, L.; Soteriadou, K.; Mazeris, A.; Ozbel, Y.; Boelaert, M. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg. Infect. Dis., 2008, 14(7), 1013-1018. (Pubitemid 351920428)
16. Machado, C.M.; Martins, T.C.; Colturato, I.; Leite, M.S.; Simione, A.J.; Souza, M.P.; Mauad, M.A.; Colturato, V.R. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev. Inst. Med. Trop. Sao Paulo, 2009, 51(6), 309-324.
17. Postigo, J.A. Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int. J. Antimicrob. Agents, 2010, 36(1), 62-65.
18. Ponirovskii, E.N.; Strelkova, M.V.; Goncharov, D.B.; Zhirenkina, E.N.; Chernikova Iu, A. [Visceral leishmaniasis in the Commonwealth of Independent States (CIS): results and basic lines of further study]. Med. Parazitol. (Mosk.), 2006, 4, 25-31.
19. Sacks, D.; Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol., 2002, 2(11), 845-858. (Pubitemid 37328707)
20. Mougneau, E.; Bihl, F.; Glaichenhaus, N. Cell biology and immunology of Leishmania. Immunol. Rev., 2011, 240(1), 286-296.
21. Handman, E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev., 2001, 14(2), 229-243.
22. Nadim, A.J.; Javadian E.; Mohebali, M. The experience of leishmanization in the Islamic Republic of Iran. East. Mediterr. Health J., 1997, 3(2), 284-289. (Pubitemid 127468704)
23. Nogueira, F.S.; Moreira, M.A.; Borja-Cabrera, G.P.; Santos, F.N.; Menz, I.; Parra, L.E.; Xu, Z.; Chu, H.J.; Palatnik-de-Sousa, C.B.; Luvizotto, M.C. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine, 2005, 23(40), 4805-4810. (Pubitemid 41242874)
24. Mock, B.A.; Fortier, A.H.; Potter, M.; Nacy, C.A. Genetic control of systemic Leishmania major infections: dissociation of intrahepatic amastigote replication from control by the Lsh gene. Infect. Immun., 1985, 50(2), 588-591. (Pubitemid 16246287)
25. Vidal, S.M.; Malo, D.; Vogan, K.; Skamene, E.; Gros, P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell, 1993, 73(3), 469-485. (Pubitemid 23143347)
26. Demant, P.; Lipoldová, M.; Svobodová, M. Resistance to Leishmania major in mice. Science, 1996, 274(5291), 1392a.
27. Beebe, A.M.; Mauze, S.; Schork, N.J.; Coffman, R.L. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity, 1997, 6(5), 551-557. (Pubitemid 27239346)
28. Lipoldová, M.; Svobodová, M.; Krulová, M.; Havelková, H.; Badalová, J.; Noh?nková, E.; Holá?, V.; Hart, A.A.; Volf, P.; Demant, P. Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes. Genes Immun., 2000, 1(3), 200-206.
29. Vladimirov, V.; Badalová, J.; Svobodová, M.; Havelková, H.; Hart, A.A.; Blažková, H.; Demant, P.; Lipoldová, M. Different genetic control of cutaneous and visceral disease after Leishmania major infection in mice. Infect. Immun., 2003, 71(4), 2041-2046. (Pubitemid 36368738)
30. Sakthianandeswaren, A.; Curtis, J.M.; Elso, C.; Kumar, B.; Baldwin, T.M.; Lopaticki, S.; Kedzierski, L.; Smyth, G.K.; Foote, S.J.; Handman, E. Fine mapping of Leishmania major susceptibility locus lmr2 and evidence of a role for Fli1 in disease and wound healing. Infect. Immun., 2010, 78(6), 2734-2744.
31. Kellina, O.I.; Strelkova, M.V. [Investigations on leishmaniases at the E.I. Martsinovsky Institute of Medical Parasitology and Tropical Medicine]. Med. Parazitol. (Mosk.), 2010, 4, 19-22.
32. Gafurov, I.M. [Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan]. Med. Parazitol. (Mosk.), 1999, 1, 58-59.
33. Amini, H. Cutaneous lesions with very long duration as a complication of leishmanization. Iranian J. Publ. Health, 1991, 20(1-4), 43-49.
34. Khamesipour, A.; Dowlati, Y.; Asilian, A.; Hashemi-Fesharki, R.; Javadi, A.; Noazin, S.; Modabber, F. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine, 2005, 23(28), 3642-3648. (Pubitemid 40692409)
35. Grekov, I.; Svobodová, M.; Noh?nková, E.; Lipoldová, M. Preparation of highly infective Leishmania promastigotes by cultivation on SNB-9 biphasic medium. J. Microbiol. Methods, 2011, 87, 273-277.
36. Hill, J.O.; North, R.J.; Collins, F.M. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect. Immun., 1983, 39(3), 1087-1094. (Pubitemid 13159945)
37. Aebischer, T.; Moody, S.F.; Handman, E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun., 1993, 61(1), 220-226. (Pubitemid 23015420)
38. Alvar, J.; Aparicio, P.; Aseffa, A.; Den Boer, M.; Canavate, C.; Dedet, J.P.; Gradoni, L.; Ter Horst, R.; Lopez-Velez, R.; Moreno, J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev., 2008, 21(2), 334-359. (Pubitemid 351555511)
39. Jenner, E. An inquiry into the causes and effects of the Variolae Vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox; Sampson Low: London, 1798. http://www.gutenberg.org/files/29414/29414-h/29414-h.htm (accessed September 7, 2011)
40. Breton, M.; Tremblay, M.J.; Ouellette, M.; Papadopoulou, B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun., 2005, 73(10), 6372-6382. (Pubitemid 41368798)
41. Azizi, H.; Hassani, K.; Taslimi, Y.; Najafabadi, H.S.; Papadopoulou, B.; Rafati, S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology, 2009, 136(7), 723-735.
42. Mizbani, A.; Taslimi, Y.; Zahedifard, F.; Taheri, T.; Rafati, S. Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae. Parasitol. Res., 2011, 109(3), 793-799.
43. Alexander, J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans. R. Soc. Trop. Med. Hyg., 1982, 76(5), 646-649. (Pubitemid 13243609)
44. Rivier, D.; Shah, R.; Bovay, P.; Mauel, J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol., 1993, 15(2), 75-84. (Pubitemid 23062427)
45. Marchand, M.; Daoud, S.; Titus, R.G.; Louis, J.; Boon, T. Variants with reduced virulence derived from Leishmania major after mutagen treatment. Parasite Immunol., 1987, 9(1), 81-92. (Pubitemid 17026571)
46. Gorczynski, R.M. Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell Immunol., 1985, 94(1), 11-20. (Pubitemid 15247791)
47. Mitchell, G.F.; Handman, E.; Spithill, T.W. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust. J. Exp. Biol. Med. Sci., 1984, 62(2), 145-53. (Pubitemid 14058198)
48. Daneshvar, H.; Coombs, G.H.; Hagan, P.; Phillips, R.S. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis., 2003, 187(10), 1662-1668. (Pubitemid 36578973)
49. Daneshvar, H.; Molaei, M.M.; Kamiabi, H.; Burchmore, R.; Hagan, P.; Phillips, R.S. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol., 2010, 32(11-12), 722-730.
50. Cruz, A.; Coburn, C.M.; Beverley, S.M. Double targeted gene replacement for creating null mutants. Proc. Natl. Acad. Sci. USA, 1991, 88(16), 7170-7174. (Pubitemid 21915111)
51. Titus, R.G.; Gueiros-Filho, F.J.; de Freitas, L.A.; Beverley, S.M. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA, 1995, 92(22), 10267-10271.
52. Veras, P.; Brodskyn, C.; Balestieri, F.; Freitas, L.; Ramos, A.; Queiroz, A.; Barral, A.; Beverley, S.; Barral-Netto, M. A dhfr-ts-Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz, 1999, 94(4), 491-496. (Pubitemid 129572523)
53. Amaral, V.F.; Teva, A.; Oliveira-Neto, M.P.; Silva, A.J.; Pereira, M.S.; Cupolillo, E.; Porrozzi, R.; Coutinho, S.G.; Pirmez, C.; Beverley, S.M.; Grimaldi, G., Jr. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz, 2002, 97(7), 1041-1048. (Pubitemid 135747502)
54. Alexander, J.; Coombs, G.H.; Mottram, J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol., 1998, 161(12), 6794-6801. (Pubitemid 28562223)
55. Papadopoulou, B.; Roy, G.; Breton, M.; Kundig, C.; Dumas, C.; Fillion, I.; Singh, A.K.; Olivier, M.; Ouellette, M. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun., 2002, 70(1), 62-68. (Pubitemid 34028599)
56. Uzonna, J.E.; Spath, G.F.; Beverley, S.M.; Scott, P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol., 2004, 172(6), 3793-3797. (Pubitemid 38337964)
57. Silvestre, R.; Cordeiro-Da-Silva, A.; Santarem, N.; Vergnes, B.; Sereno, D.; Ouaissi, A. SIR2-deficient Leishmania infantum induces a defined IFNgamma/IL-10 pattern that correlates with protection. J. Immunol., 2007, 179(5), 3161-3170.
58. Kedzierski, L.; Curtis, J.M.; Doherty, P.C.; Handman, E.; Kedzierska, K. Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by nonpersistent parasites. Eur. J. Immunol., 2008, 38(11), 3090-3100.
59. Selvapandiyan, A.; Dey, R.; Nylen, S.; Duncan, R.; Sacks, D.; Nakhasi, H.L. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol., 2009, 183(3), 1813-1820.
60. Spath, G.F.; Lye, L.F.; Segawa, H.; Sacks, D.L.; Turco, S.J.; Beverley, S.M. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science, 2003, 301(5637), 1241-1243. (Pubitemid 37052214)
61. Shankar, A.; Mitchen, T.K.; Hall, L.R.; Turco, S.J.; Titus, R.G. Reversion to virulence in Leishmania major correlates with expression of surface lipophosphoglycan. Mol. Biochem. Parasitol., 1993, 61(2), 207-216.
62. Davoudi, N.; Tate, C.A.; Warburton, C.; Murray, A.; Mahboudi, F.; McMaster, W.R. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine, 2005, 23(9), 1170-1177. (Pubitemid 40052013)
63. Kumari, S.; Samant, M.; Khare, P.; Misra, P.; Dutta, S.; Kolli, B.K.; Sharma, S.; Chang, K.P.; Dube, A. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur. J. Immunol., 2009, 39(1), 178-191.
64. Nylen, S.; Mortberg, U.; Kovalenko, D.; Satti, I.; Engstrom, K.; Bakhiet, M.; Akuffo, H. Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors. Clin. Exp. Immunol., 2001, 124(1), 43-53. (Pubitemid 32476933)
65. Nagill, R.; Mahajan, R.; Sharma, M.; Kaur, S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol. Int., 2009, 58(4), 359-366.
66. Mutiso, J.M.; Macharia, J.C.; Mutisya, R.M.; Taracha, E. Subcutaneous immunization against Leishmania major-infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants. Rev. Inst. Med. Trop. Sao Paulo, 2010, 52(2), 95-100.
67. Okwor, I.; Kuriakose, S.; Uzonna, J. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine, 2010, 28(33), 5451-5457.
68. Noazin, S.; Khamesipour, A.; Moulton, L.H.; Tanner, M.; Nasseri, K.; Modabber, F.; Sharifi, I.; Khalil, E.A.; Bernal, I.D.; Antunes, C.M.; Smith, P.G. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine, 2009, 27(35), 4747-4753.
69. Modabber, F. Leishmaniasis vaccines: past, present and future. Int. J. Antimicrob. Agents, 2010, 36(1), 58-61.
70. De Luca, P.M.; Mayrink, W.; Alves, C.R.; Coutinho, S.G.; Oliveira, M.P.; Bertho, A.L.; Toledo, V.P.; Costa, C.A.; Genaro, O.; Mendonca, S.C. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine, 1999, 17(9-10), 1179-1185. (Pubitemid 29132952)
71. Tafaghodi, M.; Eskandari, M.; Khamesipour, A.; Jaafari, M.R. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp. Parasitol., 2011, 129(2), 107-114.
72. Machado-Pinto, J.; Pinto, J.; da Costa, C.A.; Genaro, O.; Marques, M.J.; Modabber, F.; Mayrink, W. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int. J. Dermatol., 2002, 41(2), 73-78. (Pubitemid 34552351)
73. Stober, C.B.; Lange, U.G.; Roberts, M.T.; Gilmartin, B.; Francis, R.; Almeida, R.; Peacock, C.S.; McCann, S.; Blackwell, J.M. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine, 2006, 24(14), 2602-2616. (Pubitemid 43290392)
74. de Matos Guedes, H.L.; Pinheiro, R.O.; Chaves, S.P.; De-Simone, S.G.; Rossi-Bergmann, B. Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine. Vaccine, 2010, 28(33), 5491-5496.
75. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.; Bartolini, E.; Capecchi, B.; Galeotti, C.L.; Luzzi, E.; Manetti, R.; Marchetti, E.; Mora, M.; Nuti, S.; Ratti, G.; Santini, L.; Savino, S.; Scarselli, M.; Storni, E.; Zuo, P.; Broeker, M.; Hundt, E.; Knapp, B.; Blair, E.; Mason, T.; Tettelin, H.; Hood, D.W.; Jeffries, A.C.; Saunders, N.J.; Granoff, D.M.; Venter, J.C.; Moxon, E.R.; Grandi, G.; Rappuoli, R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 2000, 287(5459), 1816-1820.
76. Sette, A.; Rappuoli, R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity, 2010, 33(4), 530-541.
77. Working Group on Research Priorities for Development of Leishmaniasis Vaccines, Costa, C.H.; Peters, N.C.; Maruyama, S.R.; de Brito, E.C., Jr.; Santos, I.K. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl. Trop. Dis., 2011, 5(3), e943: Available from: http://www.plosntds. org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.00 00943
78. Nagill, R.; Kaur, S. Vaccine candidates for leishmaniasis: A review. Int. Immunopharmacol., 2011, 11(10), 1464-1488.
79. Dantas-Torres, F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmissionblocking vaccine. Vet. Parasitol., 2006, 141(1-2), 1-8. (Pubitemid 44363138)
80. Palatnik-de-Sousa, C.B.; Silva-Antunes, I.; Morgado Ade, A.; Menz, I.; Palatnik, M.; Lavor, C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine, 2009, 27(27), 3505-3512.
81. Nico, D.; Claser, C.; Borja-Cabrera, G.P.; Travassos, L.R.; Palatnik, M.; Soares, I.S.; Rodrigues, M.M.; Palatnik-de-Sousa, C.B. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response. PLoS Negl. Trop. Dis., 2010, 4(11), e866.
82. Day, M.J. The immunopathology of canine vector-borne diseases. Parasit. Vectors, 2011, 4, 48.
83. Jardim, A.; Alexander, J.; Teh, H.S.; Ou, D.; Olafson, R.W. Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med., 1990, 172(2), 645-648. (Pubitemid 20248406)
84. Spitzer, N.; Jardim, A.; Lippert, D.; Olafson, R.W. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine, 1999, 17(11-12), 1298-1300. (Pubitemid 29138794)
85. Rivier, D.; Bovay, P.; Shah, R.; Didisheim, S.; Mauel, J. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol., 1999, 21(9), 461-473. (Pubitemid 29401766)
86. Jaafari, M.R.; Ghafarian, A.; Farrokh-Gisour, A.; Samiei, A.; Kheiri, M.T.; Mahboudi, F.; Barkhordari, F.; Khamesipour, A.; McMaster, W.R. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine, 2006, 24(29-30), 5708-5717. (Pubitemid 43928184)
87. Heneberg, P. Finding the smoking gun: protein tyrosine phosphatases as tools and targets of unicellular microorganisms and viruses. Curr. Med. Chem., 2012, in press.
88. Mougneau, E.; Altare, F.; Wakil, A.E.; Zheng, S.; Coppola, T.; Wang, Z.E.; Waldmann, R.; Locksley, R.M.; Glaichenhaus, N. Expression cloning of a protective Leishmania antigen. Science, 1995, 268(5210), 563-566.
89. Gonzalez-Aseguinolaza, G.; Taladriz, S.; Marquet, A.; Larraga, V. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem., 1999, 259(3), 909-916. (Pubitemid 29075523)
90. Van der Voorn, L.; Ploegh, H.L. The WD-40 repeat. FEBS Lett., 1992, 307(2), 131-134.
91. Gurunathan, S.; Sacks, D.L.; Brown, D.R.; Reiner, S.L.; Charest, H.; Glaichenhaus, N.; Seder, R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp Med., 1997, 186(7), 1137-1147. (Pubitemid 27441157)
92. Devault, A.; Banuls, A.L. The promastigote surface antigen gene family of the Leishmania parasite: differential evolution by positive selection and recombination. BMC Evol. Biol., 2008, 8, 292.
93. Handman, E.; Symons, F.M.; Baldwin, T.M.; Curtis, J.M.; Scheerlinck, J.P. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun., 1995, 63(11), 4261-4267.
94. Al-Wabel, M.A.; Tonui, W.K.; Cui, L.; Martin, S.K.; Titus, R.G. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am. J. Trop. Med. Hyg., 2007, 77(6), 1060-1065. (Pubitemid 351837793)
95. Coler, R.N.; Goto, Y.; Bogatzki, L.; Raman, V.; Reed, S.G. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun., 2007, 75(9), 4648-4654. (Pubitemid 47378126)
96. Velez, I.D.; Gilchrist, K.; Martinez, S.; Ramirez-Pineda, J.R.; Ashman, J.A.; Alves, F.P.; Coler, R.N.; Bogatzki, L.Y.; Kahn, S.J.; Beckmann, A.M.; Cowgill, K.D.; Reed, S.G.; Piazza, F.M. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine, 2009, 28(2), 329-337.
97. Chakravarty, J.; Kumar, S.; Trivedi, S.; Rai, V.K.; Singh, A.; Ashman, J.A.; Laughlin, E.M.; Coler, R.N.; Kahn, S.J.; Beckmann, A.M.; Cowgill, K.D.; Reed, S.G.; Sundar, S.; Piazza, F.M. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine, 2011, 29(19), 3531-3537.
98. Skeiky, Y.A.; Coler, R.N.; Brannon, M.; Stromberg, E.; Greeson, K.; Crane, R.T.; Webb, J.R.; Campos-Neto, A.; Reed, S.G. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine, 2002, 20(27-28), 3292-3303. (Pubitemid 35245813)
99. Gradoni, L.; Foglia Manzillo, V.; Pagano, A.; Piantedosi, D.; De Luna, R.; Gramiccia, M.; Scalone, A.; Di Muccio, T.; Oliva, G. Failure of a multisubunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine, 2005, 23(45), 5245-5251. (Pubitemid 41443430)
100. Bertholet, S.; Goto, Y.; Carter, L.; Bhatia, A.; Howard, R.F.; Carter, D.; Coler, R.N.; Vedvick, T.S.; Reed, S.G. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine, 2009, 27(50), 7036-7045.
101. Goto, Y.; Bhatia, A.; Raman, V.S.; Liang, H.; Mohamath, R.; Picone, A.F.; Vidal, S.E.; Vedvick, T.S.; Howard, R.F.; Reed, S.G. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin. Vaccine Immunol., 2011, 18(7), 1118-1124.
102. Molano, I.; Alonso, M.G.; Miron, C.; Redondo, E.; Requena, J.M.; Soto, M.; Nieto, C.G.; Alonso, C. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunop., 2003, 92(1-2), 1-13. (Pubitemid 36298678)
103. Carcelen, J.; Iniesta, V.; Fernandez-Cotrina, J.; Serrano, F.; Parejo, J.C.; Corraliza, I.; Gallardo-Soler, A.; Maranon, F.; Soto, M.; Alonso, C.; Gomez-Nieto, C. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection. Vaccine, 2009, 27(43), 5964-5973.
104. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949 Pt 1), 1465-1468.
105. Alarcon, J.B.; Waine, G.W.; McManus, D.P. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv. Parasitol., 1999, 42, 343-410.
106. Rafati, S.; Ghaemimanesh, F.; Zahedifard, F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using signal peptidase type I in BALB/c mice. Vaccine, 2006, 24(16), 3290-3297.
107. Yang, D.M.; Fairweather, N.; Button, L.L.; McMaster, W.R.; Kahl, L.P.; Liew, F.Y. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol., 1990, 145(7), 2281-2285. (Pubitemid 20343397)
108. Xu, D.; Liew, F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology, 1995, 84(2), 173-176.
109. Ahmed, S.B.; Touihri, L.; Chtourou, Y.; Dellagi, K.; Bahloul, C. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Vaccine, 2009, 27(1), 99-106.
110. Gomes, D.C.; Pinto, E.F.; de Melo, L.D.; Lima, W.P.; Larraga, V.; Lopes, U.G.; Rossi-Bergmann, B. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine, 2007, 25(12), 2168-2172. (Pubitemid 46227690)
111. Marques-da-Silva, E.A.; Coelho, E.A.; Gomes, D.C.; Vilela, M.C.; Masioli, C.Z.; Tavares, C.A.; Fernandes, A.P.; Afonso, L.C.; Rezende, S.A. Intramuscular immunization with p36 (LACK) DNA vaccine induces IFNgamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol. Res., 2005, 98(1), 67-74. (Pubitemid 41670563)
112. Doroud, D.; Zahedifard, F.; Vatanara, A.; Najafabadi, A.R.; Taslimi, Y.; Vahabpour, R.; Torkashvand, F.; Vaziri, B.; Rafati, S. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J. Control. Release, 2011, 153(2), 154-162.
113. Ivens, A.C.; Peacock, C.S.; Worthey, E.A.; Murphy, L.; Aggarwal, G.; Berriman, M.; Sisk, E.; Rajandream, M.A.; Adlem, E.; Aert, R.; Anupama, A.; Apostolou, Z.; Attipoe, P.; Bason, N.; Bauser, C.; Beck, A.; Beverley, S.M.; Bianchettin, G.; Borzym, K.; Bothe, G.; Bruschi, C.V.; Collins, M.; Cadag, E.; Ciarloni, L.; Clayton, C.; Coulson, R.M.; Cronin, A.; Cruz, A.K.; Davies, R.M.; De Gaudenzi, J.; Dobson, D.E.; Duesterhoeft, A.; Fazelina, G.; Fosker, N.; Frasch, A.C.; Fraser, A.; Fuchs, M.; Gabel, C.; Goble, A.; Goffeau, A.; Harris, D.; Hertz-Fowler, C.; Hilbert, H.; Horn, D.; Huang, Y.; Klages, S.; Knights, A.; Kube, M.; Larke, N.; Litvin, L.; Lord, A.; Louie, T.; Marra, M.; Masuy, D.; Matthews, K.; Michaeli, S.; Mottram, J.C.; Muller-Auer, S.; Munden, H.; Nelson, S.; Norbertczak, H.; Oliver, K.; O'Neil, S.; Pentony, M.; Pohl, T.M.; Price, C.; Purnelle, B.; Quail, M.A.; Rabbinowitsch, E.; Reinhardt, R.; Rieger, M.; Rinta, J.; Robben, J.; Robertson, L.; Ruiz, J.C.; Rutter, S.; Saunders, D.; Schafer, M.; Schein, J.; Schwartz, D.C.; Seeger, K.; Seyler, A.; Sharp, S.; Shin, H.; Sivam, D.; Squares, R.; Squares, S.; Tosato, V.; Vogt, C.; Volckaert, G.; Wambutt, R.; Warren, T.; Wedler, H.; Woodward, J.; Zhou, S.; Zimmermann, W.; Smith, D.F.; Blackwell, J.M.; Stuart, K.D.; Barrell, B.; Myler, P.J. The genome of the kinetoplastid parasite, Leishmania major. Science, 2005, 309(5733), 436-442. (Pubitemid 40994677)
114. Rohoušová, I.; Volf, P. Sand fly saliva: effects on host immune response and Leishmania transmission. Folia Parasitol. (Praha), 2006, 53(3), 161-171. (Pubitemid 44582217)
115. Teixeira, C.; Gomes, R.; Collin, N.; Reynoso, D.; Jochim, R.; Oliveira, F.; Seitz, A.; Elnaiem, D.E.; Caldas, A.; de Souza, A.P.; Brodskyn, C.I.; de Oliveira, C.I.; Mendonca, I.; Costa, C.H.; Volf, P.; Barral, A.; Kamhawi, S.; Valenzuela, J.G. Discovery of markers of exposure specific to bites of Lutzomyia longipalpis, the vector of Leishmania infantum chagasi in Latin America. PLoS Negl. Trop. Dis., 2010, 4(3), e638.
116. Theodos, C.M.; Titus, R.G. Salivary gland material from the sand fly Lutzomyia longipalpis has an inhibitory effect on macrophage function in vitro. Parasite Immunol., 1993, 15(8), 481-487. (Pubitemid 23248601)
117. Rohoušová, I.; Ozensoy, S.; Ozbel, Y.; Volf, P. Detection of species-specific antibody response of humans and mice bitten by sand flies. Parasitology, 2005, 130(5), 493-499. (Pubitemid 40685764)
118. Kato, H.; Anderson, J.M.; Kamhawi, S.; Oliveira, F.; Lawyer, P.G.; Pham, V.M.; Sangare, C.S.; Samake, S.; Sissoko, I.; Garfield, M.; Sigutova, L.; Volf, P.; Doumbia, S.; Valenzuela, J.G. High degree of conservancy among secreted salivary gland proteins from two geographically distant Phlebotomus duboscqi sandflies populations (Mali and Kenya). BMC Genomics, 2006, 7, 226.
119. Drahota, J.; Lipoldová, M.; Volf, P.; Rohoušová, I. Specificity of anti-saliva immune response in mice repeatedly bitten by Phlebotomus sergenti. Parasite Immunol., 2009, 31(12), 766-770.
120. Gomes, R.B.; Brodskyn, C.; de Oliveira, C.I.; Costa, J.; Miranda, J.C.; Caldas, A.; Valenzuela, J.G.; Barral-Netto, M.; Barral, A. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J. Infect. Dis., 2002, 186(10), 1530-1534. (Pubitemid 35286128)
121. Rohoušová, I.; Volf, P.; Lipoldová, M. Modulation of murine cellular immune response and cytokine production by salivary gland lysate of three sand fly species. Parasite Immunol., 2005, 27(12), 469-473. (Pubitemid 41640943)
122. de Moura, T.R.; Oliveira, F.; Novais, F.O.; Miranda, J.C.; Clarencio, J.; Follador, I.; Carvalho, E.M.; Valenzuela, J.G.; Barral-Netto, M.; Barral, A.; Brodskyn, C.; de Oliveira, C.I. Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl. Trop. Dis., 2007, 1(2), e84.
123. Rohoušová, I.; Hostomská, J.; Vlková, M.; Kobets, T.; Lipoldová, M.; Volf, P., The protective effect against Leishmania infection conferred by sand fly bites is limited to short-term exposure. Int. J. Parasitol., 2011.
124. Morris, R.V.; Shoemaker, C.B.; David, J.R.; Lanzaro, G.C.; Titus, R.G. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol., 2001, 167(9), 5226-5230. (Pubitemid 33009759)
125. Xu, X.; Oliveira, F.; Chang, B.W.; Collin, N.; Gomes, R.; Teixeira, C.; Reynoso, D.; My Pham, V.; Elnaiem, D.E.; Kamhawi, S.; Ribeiro, J.M.; Valenzuela, J.G.; Andersen, J.F. Structure and function of a "Yellow" protein from saliva of the sand fly Lutzomyia longipalpis that confers protective immunity against Leishmania major infection. J. Biol. Chem., 2011, 286(37), 32383-32393.
126. Valenzuela, J.G.; Belkaid, Y.; Garfield, M.K.; Mendez, S.; Kamhawi, S.; Rowton, E.D.; Sacks, D.L.; Ribeiro, J.M. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med., 2001, 194(3), 331-342. (Pubitemid 32730807)
127. Oliveira, F.; Lawyer, P.G.; Kamhawi, S.; Valenzuela, J.G. Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl. Trop. Dis., 2008, 2(4), e226.
128. Tabbara, K.S.; Peters, N.C.; Afrin, F.; Mendez, S.; Bertholet, S.; Belkaid, Y.; Sacks, D.L. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun., 2005, 73(8), 4714-4722. (Pubitemid 41105627)
129. Sjölander, A.; Baldwin, T.M.; Curtis, J.M.; Bengtsson, K.L.; Handman, E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine, 1998, 16(20), 2077-2084. (Pubitemid 28473959)
130. Campos-Neto, A. In: Leishmania. Farrel, J.P., Ed.; Kluwer Academic Publishers: Boston, 2002; Vol. 4, pp 169-190.
131. Havelková, H.; Badalová, J.; Svobodová, M.; Vojtíšková, J.; Kurey, I.; Vladimirov, V.; Demant, P.; Lipoldová, M. Genetics of susceptibility to leishmaniasis in mice: four novel loci and functional heterogeneity of gene effects. Genes Immun., 2006, 7(3), 220-233.
132. Kurey, I.; Kobets, T.; Havelková, H.; Slapni?ková, M.; Quan, L.; Trtková, K.; Grekov, I.; Svobodová, M.; Stassen, A.P.; Hutson, A.; Demant, P.; Lipoldová, M. Distinct genetic control of parasite elimination, dissemination, and disease after Leishmania major infection. Immunogenetics, 2009, 61(9), 619-633.
133. Lipoldová, M.; Svobodová, M.; Havelková, H.; Krulová, M.; Badalová, J.; Noh?nková, E.; Hart, A.A.; Schlegel, D.; Volf, P.; Demant, P. Mouse genetic model for clinical and immunological heterogeneity of leishmaniasis. Immunogenetics, 2002, 54(3), 174-183. (Pubitemid 34666943)
134. Babay, B.E.; Louzir, H.; Kebaier, C.; Boubaker, S.; Dellagi, K.; Cazenave, P.A. Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major. Infect. Immun., 2004, 72(8), 4603-4611. (Pubitemid 38989319)
135. Benhnini, F.; Chenik, M.; Laouini, D.; Louzir, H.; Cazenave, P.A.; Dellagi, K. Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains. Clin. Vaccine Immunol., 2009, 16(11), 1529-1537.
136. Schroeder, J.; Brown, N.; Kaye, P.; Aebischer, T. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. PLoS Negl. Trop. Dis., 2011, 5(12): e1406.
137. Paape, D.; Aebischer, T. Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development. J. Proteomics, 2011, 74(9), 1614-1624.
138. Jensen, K.D.; Sercarz, E.E.; Gabaglia, C.R. Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase). Mol. Immunol., 2009, 46(3), 366-374.
139. Danesh-Bahreini, M.A.; Shokri, J.; Samiei, A.; Kamali-Sarvestani, E.; Barzegar-Jalali, M.; Mohammadi-Samani, S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int. J. Nanomedicine, 2011, 6, 835-842.
140. Remer, K.A.; Roeger, B.; Hambrecht, C.; Moll, H. Natural killer cells support the induction of protective immunity during dendritic cell-mediated vaccination against Leishmania major. Immunology, 2010, 131(4), 570-582.
141. Schnitzer, J.K.; Berzel, S.; Fajardo-Moser, M.; Remer, K.A.; Moll, H. Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against Leishmania major. Vaccine, 2010, 28(36), 5785-5793.
142. Agallou, M.; Margaroni, M.; Karagouni, E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine, 2011, 29(31), 5053-5064.
143. Claborn, D.M. The biology and control of leishmaniasis vectors. J. Glob. Infect. Dis., 2010, 2(2), 127-134.
144. Daneshvar, H.; Hagan, P.; Phillips, R.S. Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice. Parasite Immunol., 2003, 25(11-12), 589-596. (Pubitemid 38445402)
145. Armijos, R.X.; Weigel, M.M.; Aviles, H.; Maldonado, R.; Racines, J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis., 1998, 177(5), 1352-1357. (Pubitemid 28194278)
146. Armijos, R.X.; Weigel, M.M.; Romero, L.; Garcia, V.; Salazar, J. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last? J. Infect. Dis., 2003, 187(12), 1959-1961. (Pubitemid 36724495)
147. Armijos, R.X.; Weigel, M.M.; Calvopina, M.; Hidalgo, A.; Cevallos, W.; Correa, J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine, 2004, 22(9-10), 1320-1326. (Pubitemid 38296677)
148. Velez, I.D.; Gilchrist, K.; Arbelaez, M.P.; Rojas, C.A.; Puerta, J.A.; Antunes, C.M.; Zicker, F.; Modabber, F. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. R. Soc. Trop. Med. Hyg., 2005, 99(8), 593-598. (Pubitemid 40823865)
149. Parra, L.E.; Borja-Cabrera, G.P.; Santos, F.N.; Souza, L.O.; Palatnik-de-Sousa, C.B.; Menz, I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine, 2007, 25(12), 2180-2186. (Pubitemid 46242143)
150. Noormohammadi, A.H.; Hochrein, H.; Curtis, J.M.; Baldwin, T.M.; Handman, E., Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen. Vaccine, 2001, 19(28-29), 4043-4052. (Pubitemid 32566330)
151. Doroud, D.; Zahedifard, F.; Vatanara, A.; Najafabadi, A.R.; Rafati, S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol., 2011, 33(6), 335-348.
152. Jayakumar, A.; Castilho, T.M.; Park, E.; Goldsmith-Pestana, K.; Blackwell, J.M.; McMahon-Pratt, D. TLR1/2 activation during heterologous primeboost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl. Trop. Dis., 2011, 5(6), e1204.
153. Rodriguez, N.; Guzman, B.; Rodas, A.; Takiff, H.; Bloom, B.R.; Convit, J. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J. Clin. Microbiol., 1994, 32(9), 2246-2252.
154. Kobets, T.; Badalová, J.; Grekov, I.; Havelková, H.; Svobodová, M.; Lipoldová, M. Leishmania parasite detection and quantification using PCRELISA. Nat. Protoc., 2010, 5(6), 1074-1080.
155. Barreca, G.S.; Berlinghieri, M.C.; Foti, F.; Matera, G.; Foca, A. Microscopic observation of progressive immobilization of Leishmania promastigotes in acridine orange stain. J. Clin. Microbiol., 1997, 35(7), 1867-1869. (Pubitemid 27255677)
156. Noyes, H.A.; Reyburn, H.; Bailey, J.W.; Smith, D. A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan. J. Clin. Microbiol., 1998, 36(10), 2877-2881. (Pubitemid 28429408)
157. Abdullah, S.M.; Flath, B.; Presber, H.W. Comparison of different staining procedures for the flow cytometric analysis of U-937 cells infected with different Leishmania species. J. Microbiol. Methods, 1999, 37(2), 123-138. (Pubitemid 29313397)
158. Ferrua, B.; Le Fichoux, Y.; Suffia, I.; Rousseau, D.; Roptin, C.; Kubar, J. Quantitation of Leishmania infantum in tissues of infected BALB/c mouse by sandwich ELISA. J. Immunoassay Immunochem., 2001, 22(2), 165-181. (Pubitemid 32721183)
159. Weigle, K.A.; Labrada, L.A.; Lozano, C.; Santrich, C.; Barker, D.C. PCRbased diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J. Clin. Microbiol., 2002, 40(2), 601-606. (Pubitemid 34130887)
160. Royer, M.A.; Crowe, C.O. American cutaneous leishmaniasis. Arch. Pathol. Lab. Med., 2002, 126(4), 471-473.
161. Allahverdiyev, A.M.; Uzun, S.; Bagirova, M.; Durdu, M.; Memisoglu, H.R. A sensitive new microculture method for diagnosis of cutaneous leishmaniasis. Am. J. Trop. Med. Hyg., 2004, 70(3), 294-297. (Pubitemid 38366534)
162. Sipahi, T.; Tavil, B.; Oksal, A. Visceral leishmaniasis and Pseudomonas septicemia associated with hemophagocytic syndrome and myelodysplasia in a Turkish child. Turk. J. Pediatr., 2005, 47(2), 191-194. (Pubitemid 40767223)
163. Saleem, K.; Ayaz, B.; Shaikh, A. Histological grading patterns in patients of cutaneous leishmaniasis. J. Coll. Physicians Surg. Pak., 2007, 17(11), 650-653.
164. Weiss, F.; Vogenthaler, N.; Franco-Paredes, C.; Parker, S.R. Leishmania tropica-induced cutaneous and presumptive concomitant viscerotropic leishmaniasis with prolonged incubation. Arch. Dermatol., 2009, 145(9), 1023-1026.
165. Akhavan, A.A.; Mirhendi, H.; Khamesipour, A.; Alimohammadian, M.H.; Rassi, Y.; Bates, P.; Kamhawi, S.; Valenzuela, J.G.; Arandian, M.H.; Abdoli, H.; Jalali-zand, N.; Jafari, R.; Shareghi, N.; Ghanei, M.; Yaghoobi-Ershadi, M.R. Leishmania species: detection and identification by nested PCR assay from skin samples of rodent reservoirs. Exp. Parasitol., 2010, 126(4), 552-556.
166. Michel, G.; Ferrua, B.; Lang, T.; Maddugoda, M.P.; Munro, P.; Pomares, C.; Lemichez E.; Marty, P. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl. Trop. Dis., 2011, 5(9), e1323. Available from: http://www.plosntds.org/ article/info%3Adoi%2F10.1371%2Fjournal.pntd.00 01323
167. Lecoeur, H.; Buffet, P.; Morizot, G.; Goyard, S.; Guigon, G.; Milon, G.; Lang, T. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 model. PLoS Negl. Trop. Dis., 2007, 1(2), e34.
168. Filipe-Santos, O.; Pescher, P.; Breart, B.; Lippuner, C.; Aebischer, T.; Glaichenhaus, N.; Spath, G.F.; Bousso, P. A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection. Cell Host Microbe, 2009, 6(1), 23-33.
169. Courret, N.; Frehel, C.; Gouhier, N.; Pouchelet, M.; Prina, E.; Roux, P.; Antoine, J.C. Biogenesis of Leishmania-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. J. Cell Sci., 2002, 115(11), 2303-2316. (Pubitemid 34752974)
170. Shahbazi, F.; Shahabi, S.; Kazemi, B.; Mohebali, M.; Abadi, A.R.; Zare, Z. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol. Res., 2008, 103(5), 1159-1162.
171. Spanakos, G.; Patsoula, E.; Kremastinou, T.; Saroglou, G.; Vakalis, N. Development of a PCR-based method for diagnosis of Leishmania in blood samples. Mol. Cell. Probes, 2002, 16(6), 415-420. (Pubitemid 36005730)
172. Titus, R.G.; Marchand, M.; Boon, T.; Louis, J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol., 1985, 7(5), 545-555. (Pubitemid 16256170)
173. Lima, H.C.; Bleyenberg, J.A.; Titus, R.G., A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today, 1997, 13(2), 80-82. (Pubitemid 27080903)
174. Boggild, A.K.; Miranda-Verastegui, C.; Espinosa, D.; Arevalo, J.; Martinez-Medina, D.; Llanos-Cuentas, A.; Low, D.E. Optimization of microculture and evaluation of miniculture for the isolation of Leishmania parasites from cutaneous lesions in Peru. Am. J. Trop. Med. Hyg., 2008, 79(6), 847-852.
175. Rioux, J.A.; Lanotte, G.; Serres, E.; Pratlong, F.; Bastien, P.; Perieres, J. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann. Parasitol. Hum. Comp., 1990, 65(3), 111-125.
176. Mauricio, I.L.; Yeo, M.; Baghaei, M.; Doto, D.; Pratlong, F.; Zemanova, E.; Dedet, J.P.; Lukes, J.; Miles, M.A. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD). Int. J. Parasitol., 2006, 36(7), 757-769. (Pubitemid 43866079)
177. Pratlong, F.; Dereure, J.; Ravel, C.; Lami, P.; Balard, Y.; Serres, G.; Lanotte, G.; Rioux, J.A.; Dedet, J.P. Geographical distribution and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. Trop. Med. Int. Health, 2009, 14(9), 1071-1085.
178. Marco, J.D.; Bhutto, A.M.; Soomro, F.R.; Baloch, J.H.; Barroso, P.A.; Kato, H.; Uezato, H.; Katakura, K.; Korenaga, M.; Nonaka, S.; Hashiguchi, Y. Multilocus enzyme electrophoresis and cytochrome B gene sequencingbased identification of Leishmania isolates from different foci of cutaneous leishmaniasis in Pakistan. Am. J. Trop. Med. Hyg., 2006, 75(2), 261-266. (Pubitemid 46941341)
179. Marco, J.D.; Uezato, H.; Mimori, T.; Barroso, P.A.; Korenaga, M.; Nonaka, S.; Basombrio, M.A.; Taranto, N.J.; Hashiguchi, Y. Are cytochrome B gene sequencing and polymorphism-specific polymerase chain reaction as reliable as multilocus enzyme electrophoresis for identifying Leishmania spp. from Argentina? Am. J. Trop. Med. Hyg., 2006, 75(2), 256-260. (Pubitemid 46941340)
180. Rodgers, M.R.; Popper, S.J.; Wirth, D.F. Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania. Exp. Parasitol., 1990, 71(3), 267-275. (Pubitemid 20340950)
181. Volpini, A.C.; Marques, M.J.; Lopes dos Santos, S.; Machado-Coelho, G.L.; Mayrink, W.; Romanha, A.J. Leishmania identification by PCR of Giemsastained lesion imprint slides stored for up to 36 years. Clin. Microbiol. Infect., 2006, 12(8), 815-818.
182. Van Eys, G.J.; Schoone, G.J.; Kroon, N.C.; Ebeling, S.B. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol. Biochem. Parasitol., 1992, 51(1), 133-142.
183. Espinosa, D.; Boggild, A.K.; Deborggraeve, S.; Laurent, T.; Valencia, C.; Pacheco, R.; Miranda-Verastegui, C.; Llanos-Cuentas, A.; Leclipteux, T.; Dujardin, J.C.; Buscher, P.; Arevalo, J. Leishmania OligoC-TesT as a simple, rapid, and standardized tool for molecular diagnosis of cutaneous leishmaniasis in Peru. J. Clin. Microbiol., 2009, 47(8), 2560-2563.
184. Roelfsema, J.H.; Nozari, N.; Herremans, T.; Kortbeek, L.M.; Pinelli, E. Evaluation and improvement of two PCR targets in molecular typing of clinical samples of Leishmania patients. Exp. Parasitol., 2011, 127(1), 36-41.
185. Katakura, K.; Kawazu, S.; Naya, T.; Nagakura, K.; Ito, M.; Aikawa, M.; Qu, J.Q.; Guan, L.R.; Zuo, X.P.; Chai, J.J.; Chang, K.P.; Matsumoto, Y. Diagnosis of kala-azar by nested PCR based on amplification of the Leishmania mini-exon gene. J. Clin. Microbiol., 1998, 36(8), 2173-2177. (Pubitemid 28324060)
186. Nasereddin, A.; Bensoussan-Hermano, E.; Schonian, G.; Baneth, G.; Jaffe, C.L. Molecular diagnosis of Old World cutaneous leishmaniasis and species identification by use of a reverse line blot hybridization assay. J. Clin. Microbiol., 2008, 46(9), 2848-2855.
187. Azmi, K.; Nasereddin, A.; Ereqat, S.; Schonian, G.; Abdeen, Z. Identification of Old World Leishmania species by PCR-RFLP of the 7 spliced leader RNA gene and reverse dot blot assay. Trop. Med. Int. Health, 2010, 15(8), 872-880.
188. Tupperwar, N.; Vineeth, V.; Rath, S.; Vaidya, T. Development of a real-time polymerase chain reaction assay for the quantification of Leishmania species and the monitoring of systemic distribution of the pathogen. Diagn. Microbiol. Infect. Dis., 2008, 61(1), 23-30. (Pubitemid 351509751)
189. Fraga, J.; Montalvo, A.M.; De Doncker, S.; Dujardin, J.C.; Van der Auwera, G. Phylogeny of Leishmania species based on the heat-shock protein 70 gene. Infect. Genet. Evol., 2010, 10(2), 238-245.
190. Da Silva, L.A.; de Sousa Cdos, S.; da Graca, G.C.; Porrozzi, R.; Cupolillo, E. Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in Brazil. Infect. Genet. Evol., 2010, 10(1), 77-83.
191. Croan, D.G.; Morrison, D.A.; Ellis, J.T. Evolution of the genus Leishmania revealed by comparison of DNA and RNA polymerase gene sequences. Mol. Biochem. Parasitol., 1997, 89(2), 149-159. (Pubitemid 27435089)
192. Asato, Y.; Oshiro, M.; Myint, C.K.; Yamamoto, Y.; Kato, H.; Marco, J.D.; Mimori, T.; Gomez, E.A.; Hashiguchi, Y.; Uezato, H. Phylogenic analysis of the genus Leishmania by cytochrome b gene sequencing. Exp. Parasitol., 2009, 121(4), 352-361.
193. Zemanova, E.; Jirku, M.; Mauricio, I.L.; Horak, A.; Miles, M.A.; Lukes, J. The Leishmania donovani complex: genotypes of five metabolic enzymes (ICD, ME, MPI, G6PDH, and FH), new targets for multilocus sequence typing. Int. J. Parasitol., 2007, 37(2), 149-160. (Pubitemid 46091787)
194. Castilho, T.M.; Camargo, L.M.; McMahon-Pratt, D.; Shaw, J.J.; Floeter-Winter, L.M. A real-time polymerase chain reaction assay for the identification and quantification of American Leishmania species on the basis of glucose-6-phosphate dehydrogenase. Am. J. Trop. Med. Hyg., 2008, 78(1), 122-132. (Pubitemid 351844506)
195. Oshaghi, M.A.; Ravasan, N.M.; Hide, M.; Javadian, E.A.; Rassi, Y.; Sedaghat, M.M.; Mohebali, M.; Hajjaran, H. Development of speciesspecific PCR and PCR-restriction fragment length polymorphism assays for L. infantum/L. donovani discrimination. Exp. Parasitol., 2009, 122(1), 61-65.
196. Nicolas, L.; Prina, E.; Lang, T.; Milon, G. Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J. Clin. Microbiol., 2002, 40(5), 1666-1669. (Pubitemid 34493137)
197. Bensoussan, E.; Nasereddin, A.; Jonas, F.; Schnur, L.F.; Jaffe, C.L. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J. Clin. Microbiol., 2006, 44(4), 1435-1439.
198. de Toledo, J.S.; Junqueira dos Santos, A.F.; Rodrigues de Moura, T.; Antoniazi, S.A.; Brodskyn, C.; Indiani de Oliveira, C.; Barral, A.; Cruz, A.K. Leishmania (Viannia) braziliensis transfectants overexpressing the miniexon gene lose virulence in vivo. Parasitol. Int., 2009, 58(1), 45-50.
199. Mary, C.; Faraut, F.; Lascombe, L.; Dumon, H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J. Clin. Microbiol., 2004, 42(11), 5249-5255. (Pubitemid 39506237)
200. Rolao, N.; Cortes, S.; Rodrigues, O.R.; Campino, L. Quantification of Leishmania infantum parasites in tissue biopsies by real-time polymerase chain reaction and polymerase chain reaction-enzyme-linked immunosorbent assay. J. Parasitol., 2004, 90(5), 1150-1154. (Pubitemid 40247397)
201. Parvizi, P.; Baghban, N.; Novin, E.A.; Absavaran, A. Detection, identification and molecular typing of Leishmania major in Phlebotomus papatasi from a focus of zoonotic cutaneous leishmaniasis in central of Iran. Exp. Parasitol., 2010, 124(2), 232-237.
202. Gausterer, C.; Stein, C.; Stimpfl, T., Application of direct PCR in a forensic case of yew poisoning. Int. J. Legal Med., 2011, in press.
203. Jung, S.J.; Bae, M.J.; Oh, M.J.; Lee, J. Sequence conservation in the internal transcribed spacers and 5.8S ribosomal RNA of parasitic scuticociliates Miamiensis avidus (Ciliophora, Scuticociliatia). Parasitol. Int., 2011, 60(2), 216-219.
204. de Lima, V.M.; Fattori, K.R.; Michelin Ade, F.; da Silveira Neto, L.; Vasconcelos Rde, O. Comparison between ELISA using total antigen and immunochromatography with antigen rK39 in the diagnosis of canine visceral leishmaniasis. Vet. Parasitol., 2010, 173(3-4), 330-333.
205. Pinero, J.; Martinez, E.; Pacheco, R.; Aragon, Z.; De Armas, F.; Del Castillo, A.; Valladares, B. PCR-ELISA for diagnosis of mucocutaneous leishmaniasis. Acta Trop., 1999, 73(1), 21-29. (Pubitemid 29238108)
206. Martin-Sanchez, J.; Lopez-Lopez, M.C.; Acedo-Sanchez, C.; Castro-Fajardo, J.J.; Pineda, J.A.; Morillas-Marquez, F. Diagnosis of infections with Leishmania infantum using PCR-ELISA. Parasitology, 2001, 122(6), 607-615. (Pubitemid 32612504)
207. Alborzi, A.; Pourabbas, B.; Shahian, F.; Mardaneh, J.; Pouladfar, G.R.; Ziyaeyan, M. Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am. J. Trop. Med. Hyg., 2008, 79(6), 839-842.
208. Deborggraeve, S.; Laurent, T.; Espinosa, D.; Van der Auwera, G.; Mbuchi, M.; Wasunna, M.; El-Safi, S.; Al-Basheer, A.A.; Arevalo, J.; Miranda-Verastegui, C.; Leclipteux, T.; Mertens, P.; Dujardin, J.C.; Herdewijn, P.; Buscher, P. A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J. Infect. Dis., 2008, 198(10), 1565-1572.
209. Fernandes, O.; Murthy, V.K.; Kurath, U.; Degrave, W.M.; Campbell, D.A. Mini-exon gene variation in human pathogenic Leishmania species. Mol. Biochem. Parasitol., 1994, 66(2), 261-271. (Pubitemid 24272073)
210. Cupolillo, E.; Grimaldi Junior, G.; Momen, H.; Beverley, S.M. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol. Biochem. Parasitol., 1995, 73(1-2), 145-155.
211. Marfurt, J.; Niederwieser, I.; Makia, N.D.; Beck, H.P.; Felger, I. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn. Microbiol. Infect. Dis., 2003, 46(2), 115-124. (Pubitemid 36703348)
212. Luyo-Acero, G.E.; Uezato, H.; Oshiro, M.; Takei, K.; Kariya, K.; Katakura, K.; Gomez-Landires, E.; Hashiguchi, Y.; Nonaka, S. Sequence variation of the cytochrome b gene of various human infecting members of the genus Leishmania and their phylogeny. Parasitology, 2004, 128(5), 483-491. (Pubitemid 38680274)
213. Hide, M.; Banuls, A.L. Species-specific PCR assay for L. infantum/L. donovani discrimination. Acta Trop., 2006, 100(3), 241-245. (Pubitemid 46176766)
214. Mimori, T.; Sasaki, J.; Nakata, M.; Gomez, E.A.; Uezato, H.; Nonaka, S.; Hashiguchi, Y.; Furuya, M.; Saya, H. Rapid identification of Leishmania species from formalin-fixed biopsy samples by polymorphism-specific polymerase chain reaction. Gene, 1998, 210(2), 179-186. (Pubitemid 28171440)
215. Lima, V.M.; Goncalves, M.E.; Ikeda, F.A.; Luvizotto, M.C.; Feitosa, M.M. Anti-Leishmania antibodies in cerebrospinal fluid from dogs with visceral leishmaniasis. Braz. J. Med. Biol. Res., 2003, 36(4), 485-489. (Pubitemid 36603277)
216. McMahon Pratt, D.; David, J.R. Monoclonal antibodies that distinguish between New World species of Leishmania. Nature, 1981, 291(5816), 581-583. (Pubitemid 11043680)
217. Zeyrek, F.Y.; Korkmaz, M.; Ozbel, Y. Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic. Clin. Vaccine Immunol., 2007, 14(11), 1409-1415. (Pubitemid 350304032)
218. Bern, C.; Jha, S.N.; Joshi, A.B.; Thakur, G.D.; Bista, M.B. Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am. J. Trop. Med. Hyg., 2000, 63(3-4), 153-157. (Pubitemid 32488353)
219. Vilaplana, C.; Blanco, S.; Dominguez, J.; Gimenez, M.; Ausina, V.; C, T.U.; Munoz, C. Noninvasive method for diagnosis of visceral leishmaniasis by a latex agglutination test for detection of antigens in urine samples. J. Clin. Microbiol., 2004, 42(4), 1853-1854. (Pubitemid 38500861)
220. Montenegro, J. Cutaneous reaction in leishmaniasis. Arch. Dermatol. Syphilol., 1926, 13, 187-194.
221. Sassi, A.; Louzir, H.; Ben Salah, A.; Mokni, M.; Ben Osman, A.; Dellagi, K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin. Exp. Immunol., 1999, 116(1), 127-132. (Pubitemid 29170015)
222. Gidwani, K.; Rai, M.; Chakravarty, J.; Boelaert, M.; Sundar, S. Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg., 2009, 80(4), 566-567.
223. Bern, C.; Amann, J.; Haque, R.; Chowdhury, R.; Ali, M.; Kurkjian, K.M.; Vaz, L.; Wagatsuma, Y.; Breiman, R.F.; Secor, W.E.; Maguire, J.H. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am. J. Trop. Med. Hyg., 2006, 75(4), 744-748. (Pubitemid 46941287)
224. Foulet, F.; Botterel, F.; Buffet, P.; Morizot, G.; Rivollet, D.; Deniau, M.; Pratlong, F.; Costa, J.M.; Bretagne, S. Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J. Clin. Microbiol., 2007, 45(7), 2110-2115. (Pubitemid 47203778)
225. Singh, D.P.; Goyal, R.K.; Singh, R.K.; Sundar, S.; Mohapatra, T.M. In search of an ideal test for diagnosis and prognosis of kala-azar. J. Health Popul. Nutr., 2010, 28(3), 281-285.
226. Goto, H.; Lindoso, J.A. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther., 2010, 8(4), 419-433.
227. Croft, S.L.; Seifert, K.; Yardley, V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res., 2006, 123(3), 399-410. (Pubitemid 43905578)
228. Mishra, J.; Saxena, A.; Singh, S. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem., 2007, 14(10), 1153-1169. (Pubitemid 46679457)
229. Sundar, S.; Chatterjee, M. Visceral leishmaniasis-current therapeutic modalities. Indian J. Med. Res., 2006, 123(3), 345-352.
230. Cruz, A.K.; de Toledo, J.S.; Falade, M.; Terrao, M.C.; Kamchonwongpaisan, S.; Kyle, D.E.; Uthaipibull, C. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review. Curr. Drug Targets, 2009, 10(3), 178-192.
231. Sundar, S.; Mehta, H.; Chhabra, A.; Singh, V.; Chauhan, V.; Desjeux, P.; Rai, M. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis., 2006, 42(5), 608-613. (Pubitemid 43271372)
232. Berman, J.D.; Badaro, R.; Thakur, C.P.; Wasunna, K.M.; Behbehani, K.; Davidson, R.; Kuzoe, F.; Pang, L.; Weerasuriya, K.; Bryceson, A.D. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ., 1998, 76(1), 25-32. (Pubitemid 28254976)
233. Dietze, R.; Carvalho, S.F.; Valli, L.C.; Berman, J.; Brewer, T.; Milhous, W.; Sanchez, J.; Schuster, B.; Grogl, M. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg., 2001, 65(6), 685-689. (Pubitemid 34049456)
234. Wasunna, M.K.; Rashid, J.R.; Mbui, J.; Kirigi, G.; Kinoti, D.; Lodenyo, H.; Felton, J.M.; Sabin, A.J.; Albert, M.J.; Horton, J. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg., 2005, 73(5), 871-876. (Pubitemid 41688461)
235. Jha, T.K.; Sundar, S.; Thakur, C.P.; Felton, J.M.; Sabin, A.J.; Horton, J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg., 2005, 73(6), 1005-1011. (Pubitemid 43038244)
236. Denton, H.; McGregor, J.C.; Coombs, G.H. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J., 2004, 381(2), 405-412. (Pubitemid 38969684)
237. Mottram, J.C.; Coombs, G.H. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol., 1985, 59(2), 151-160. (Pubitemid 15110104)
238. Berman, J.D.; Waddell, D.; Hanson, B.D. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother., 1985, 27(6), 916-920. (Pubitemid 15062736)
239. Berman, J.D.; Gallalee, J.V.; Best, J.M. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol., 1987, 36(2), 197-201. (Pubitemid 17004915)
240. Wyllie, S.; Cunningham, M.L.; Fairlamb, A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem., 2004, 279(38), 39925-39932. (Pubitemid 39258265)
241. Legare, D.; Papadopoulou, B.; Roy, G.; Mukhopadhyay, R.; Haimeur, A.; Dey, S.; Grondin, K.; Brochu, C.; Rosen, B.P.; Ouellette, M. Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp. Parasitol., 1997, 87(3), 275-282. (Pubitemid 27494332)
242. Mukhopadhyay, R.; Dey, S.; Xu, N.; Gage, D.; Lightbody, J.; Ouellette, M.; Rosen, B.P. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA, 1996, 93(19), 10383-10387. (Pubitemid 26314631)
243. Chakraborty, A.K.; Majumder, H.K. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem. Biophys. Res. Commun., 1988, 152(2), 605-611.
244. Gonzalez, U.; Pinart, M.; Reveiz, L.; Alvar, J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst. Rev., 2008, 4, CD005067.
245. Uzun, S.; Durdu, M.; Culha, G.; Allahverdiyev, A.M.; Memisoglu, H.R. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J. Parasitol., 2004, 90(4), 853-859. (Pubitemid 39128745)
246. Firdous, R.; Yasinzai, M.; Ranja, K. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis. Int. J. Dermatol., 2009, 48(7), 758-762.
247. Bermudez, H.; Rojas, E.; Garcia, L.; Desjeux, P.; Dujardin, J.C.; Boelaert, M.; Chappuis, F. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann. Trop. Med. Parasitol., 2006, 100(7), 591-600. (Pubitemid 46940781)
248. Oliveira-Neto, M.P.; Schubach, A.; Mattos, M.; Goncalves-Costa, S.C.; Pirmez, C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg., 1997, 57(6), 651-655. (Pubitemid 28049378)
249. Palacios, R.; Osorio, L.E.; Grajalew, L.F.; Ochoa, M.T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg., 2001, 64(3-4), 187-193. (Pubitemid 32565849)
250. Maltezou, H.C. Drug resistance in visceral leishmaniasis. J. Biomed. Biotechnol., 2010, 2010, 617521.
251. Olliaro, P.L.; Guerin, P.J.; Gerstl, S.; Haaskjold, A.A.; Rottingen, J.A.; Sundar, S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis., 2005, 5(12), 763-774. (Pubitemid 41688981)
252. Vanaerschot, M.; De Doncker, S.; Rijal, S.; Maes, L.; Dujardin, J.C.; Decuypere, S. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden. PLoS One, 2011, 6(8), e23120.
253. Carter, K.C.; Hutchison, S.; Henriquez, F.L.; Legare, D.; Ouellette, M.; Roberts, C.W.; Mullen, A.B. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gammaglutamylcysteine synthetase. Antimicrob. Agents Chemother., 2006, 50(1), 88-95. (Pubitemid 43042907)
254. Downing, T.; Imamura, H.; Decuypere, S.; Clark, T.G.; Coombs, G.H.; Cotton, J.A.; Hilley, J.D.; de Doncker, S.; Maes, I.; Mottram, J.C.; Quail, M.A.; Rijal, S.; Sanders, M.; Schonian, G.; Stark, O.; Sundar, S.; Vanaerschot, M.; Hertz-Fowler, C.; Dujardin, J.C.; Berriman, M. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res., 2011, 21(12), 2143-2156.
255. Perry, M.R.; Wyllie, S.; Prajapati, V.K.; Feldmann, J.; Sundar, S.; Boelaert, M.; Fairlamb, A.H. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent? PLoS Negl. Trop. Dis., 2011, 5(9), e1227.
256. Moore, E.M.; Lockwood, D.N. Treatment of visceral leishmaniasis. J. Glob. Infect. Dis., 2010, 2(2), 151-158.
257. Alving, C.R.; Steck, E.A.; Chapman, W.L.Jr.; Waits, V.B.; Hendricks, L.D.; Swartz, G.M.Jr.; Hanson, W.L. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. USA, 1978, 75(6), 2959-63. (Pubitemid 8378744)
258. Eriksson, U.; Seifert, B.; Schaffner, A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ, 2001, 322(7286), 579-582. (Pubitemid 32234532)
259. Hiemenz, J.W.; Walsh, T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis., 1996, 22(2), S133-144. (Pubitemid 26256445)
260. Sundar, S.; Jha, T.K.; Thakur, C.P.; Mishra, M.; Singh, V.P.; Buffels, R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis., 2003, 37(6), 800-804. (Pubitemid 37153659)
261. Ritmeijer, K.; Ter Horst, R.; Chane, S.; Aderie, E.M.; Piening, T.; Collin, S.M.; Davidson, R.N. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin. Infect. Dis., 2011, 53(12), e152-158.
262. Report of the Fifth Consultative Meeting on Leishmania/HIV Coinfection;
263. Sundar, S.; Murray, H.W. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J. Infect. Dis., 1996, 173(3), 762-765. (Pubitemid 26069670)
264. Moon, S.; Jambert, E.; Childs, M.; von Schoen-Angerer, T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health, 2011, 7(1), 39.
265. Tuon, F.F.; Amato, V.S.; Graf, M.E.; Siqueira, A.M.; Nicodemo, A.C.; Amato Neto, V. Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis. Int. J. Dermatol., 2008, 47(2), 109-124.
266. Verma, N.K.; Dey, C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother., 2004, 48(8), 3010-3015. (Pubitemid 38992329)
267. Luque-Ortega, J.R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51(4), 1327-1332. (Pubitemid 46586813)
268. Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Opperdoes, F.R. Ether-lipid (alkylphospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol., 2000, 111(1), 1-14.
269. Rakotomanga, M.; Blanc, S.; Gaudin, K.; Chaminade, P.; Loiseau, P.M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51(4), 1425-1430. (Pubitemid 46586825)
270. Maly, K.; Uberall, F.; Schubert, C.; Kindler, E.; Stekar, J.; Brachwitz, H.; Grunicke, H.H. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des., 1995, 10(5), 411-425.
271. Wieder, T.; Reutter, W.; Orfanos, C.E.; Geilen, C.C. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res., 1999, 38(3), 249-259. (Pubitemid 29328968)
272. Sundar, S.; Jha, T.K.; Thakur, C.P.; Engel, J.; Sindermann, H.; Fischer, C.; Junge, K.; Bryceson, A.; Berman, J. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med., 2002, 347(22), 1739-1746. (Pubitemid 35375612)
273. Chawla, B.; Jhingran, A.; Panigrahi, A.; Stuart, K.D.; Madhubala, R. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin-susceptible-resistant Leishmania donovani. PLoS One, 2011, 6(10), e26660.
274. Maarouf, M.; de Kouchkovsky, Y.; Brown, S.; Petit, P.X.; Robert-Gero, M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell Res., 1997, 232(2), 339-348. (Pubitemid 27194047)
275. Maarouf, M.; Lawrence, F.; Croft, S.L.; Robert-Gero, M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res., 1995, 81(5), 421-425.
276. Maarouf, M.; Lawrence, F.; Brown, S.; Robert-Gero, M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res., 1997, 83(2), 198-202. (Pubitemid 27080892)
277. Sundar, S.; Jha, T.K.; Thakur, C.P.; Sinha, P.K.; Bhattacharya, S.K. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med., 2007, 356(25), 2571-2581. (Pubitemid 46961002)
278. El-On, J.; Halevy, S.; Grunwald, M.H.; Weinrauch, L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a doubleblind control study. J. Am. Acad. Dermatol., 1992, 27(2), 227-231.
279. Faghihi, G.; Tavakoli-kia, R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin. Exp. Dermatol., 2003, 28(1), 13-16. (Pubitemid 36197553)
280. Ozgoztasi, O.; Baydar, I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int. J. Dermatol., 1997, 36(1), 61-63. (Pubitemid 27139758)
281. Arana, B.A.; Mendoza, C.E.; Rizzo, N.R.; Kroeger, A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg., 2001, 65(5), 466-470. (Pubitemid 33134578)
282. Neva, F.A.; Ponce, C.; Ponce, E.; Kreutzer, R.; Modabber, F.; Olliaro, P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans. R. Soc. Trop. Med. Hyg., 1997, 91(4), 473-475. (Pubitemid 27421247)
283. Pacher, P.; Nivorozhkin, A.; Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., 2006, 58(1), 87-114.
284. Kelly, J.M. Molecular mechanisms of pathogenesis in Chagas disease; Landes Bioscience, Eurekah.com, Kluwer Academic, Plenum Pub.: Georgetown, New York, 2003.
285. Martinez, S.; Gonzalez, M.; Vernaza, M.E. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin. Infect. Dis., 1997, 24(2), 165-169. (Pubitemid 27081538)
286. Velez, I.; Agudelo, S.; Hendrickx, E.; Puerta, J.; Grogl, M.; Modabber, F.; Berman, J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med., 1997, 126(3), 232-236. (Pubitemid 27061579)
287. Cozzani, E.; Satta, R.; Fausti, V.; Cottoni, F.; Parodi, A. Cutaneous sporotrichoid leishmaniasis resistant to pentavalent antimonial therapy: complete resolution with itraconazole. Clin. Exp. Dermatol., 2010, 36(1), 49-51.
288. Abadir, A.; Patel, A.; Haider, S. Systemic therapy of New World cutaneous leishmaniasis: A case report and review article. Can. J. Infect. Dis. Med. Microbiol., 2010, 21(2), e79-83: Available from: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2912102/pdf/idmm21e079.pdf
289. Emad, M.; Hayati, F.; Fallahzadeh, M.K.; Namazi, M.R. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous Leishmania major infection: a randomized clinical trial. J. Am. Acad. Dermatol., 2011, 64(3), 606-608.
290. De Oliveira-Silva, F.; de Morais-Teixeira, E.; Rabello, A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am. J. Trop. Med. Hyg., 2008, 78(5), 745-749. (Pubitemid 351845131)
291. Krolewiecki, A.J.; Romero, H.D.; Cajal, S.P.; Abraham, D.; Mimori, T.; Matsumoto, T.; Juarez, M.; Taranto, N.J. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am. J. Trop. Med. Hyg., 2007, 77(4), 640-646. (Pubitemid 351844285)
292. Carvalho, L.; Luque-Ortega, J.R.; Lopez-Martin, C.; Castanys, S.; Rivas, L.; Gamarro, F. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob. Agents Chemother., 2011, 55(9), 4204-4210.
293. van Ingen, J.; Aarnoutse, R.E.; Donald, P.R.; Diacon, A.H.; Dawson, R.; Plemper van Balen, G.; Gillespie, S.H.; Boeree, M.J. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis., 2011, 52(9), e194-199.
294. Kochar, D.K.; Aseri, S.; Sharma, B.V.; Bumb, R.A.; Mehta, R.D.; Purohit, S.K. The role of rifampicin in the management of cutaneous leishmaniasis. Q. J. M., 2000, 93(11), 733-737.
295. Curti, C.; Laget, M.; Carle, A.O.; Gellis, A.; Vanelle, P. Rapid synthesis of sulfone derivatives as potential anti-infectious agents. Eur. J. Med. Chem., 2007, 42(6), 880-884. (Pubitemid 46810072)
296. Dogra, J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 1991, 85(2), 212-213.
297. Osorio, L.E.; Palacios, R.; Chica, M.E.; Ochoa, M.T. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet, 1998, 351(9101), 498-499. (Pubitemid 28070104)
298. Bucaretchi, F.; Vicente, D.C.; Pereira, R.M.; Tresoldi, A.T. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy. Rev. Inst. Med. Trop. Sao Paulo, 2004, 46(6), 331-334. (Pubitemid 40052826)
299. van Griensven, J.; Balasegaram, M.; Meheus, F.; Alvar, J.; Lynen, L.; Boelaert, M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis., 2010, 10(3), 184-194.
300. Sundar, S.; Sinha, P.K.; Rai, M.; Verma, D.K.; Nawin, K.; Alam, S.; Chakravarty, J.; Vaillant, M.; Verma, N.; Pandey, K.; Kumari, P.; Lal, C.S.; Arora, R.; Sharma, B.; Ellis, S.; Strub-Wourgaft, N.; Balasegaram, M.; Olliaro, P.; Das, P.; Modabber, F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an openlabel, non-inferiority, randomised controlled trial. Lancet, 2011, 377(9764), 477-486.
301. El-Sayed, M.; Anwar, A.E. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J. Eur. Acad. Dermatol. Venereol., 2010, 24(3), 335-340.
302. Llanos-Cuentas, A.; Echevarria, J.; Cruz, M.; La Rosa, A.; Campos, P.; Campos, M.; Franke, E.; Berman, J.; Modabber, F.; Marr, J. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin. Infect. Dis., 1997, 25(3), 677-684. (Pubitemid 27392612)
303. Baptista, M.S.; Wainwright, M. Photodynamic antimicrobial chemotherapy (PACT) for the treatment of malaria, leishmaniasis and trypanosomiasis. Braz. J. Med. Biol. Res., 2011, 44(1), 1-10.
304. Asilian, A.; Davami, M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin. Exp. Dermatol., 2006, 31(5), 634-637. (Pubitemid 44086787)
305. Kosaka, S.; Akilov, O.E.; O'Riordan, K.; Hasan, T. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J. Invest. Dermatol., 2007, 127(6), 1546-1549. (Pubitemid 46762980)
306. Reithinger, R.; Mohsen, M.; Wahid, M.; Bismullah, M.; Quinnell, R.J.; Davies, C.R.; Kolaczinski, J.; David, J.R. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin. Infect. Dis., 2005, 40(8), 1148-1155. (Pubitemid 40490240)
307. Lobo, I.M.; Soares, M.B.; Correia, T.M.; de Freitas, L.A.; Oliveira, M.I.; Nakatani, M.; Netto, E.; Badaro, R.; David, J.R. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans. R. Soc. Trop. Med. Hyg., 2006, 100(7), 642-649.
308. Aronson, N.E.; Wortmann, G.W.; Byrne, W.R.; Howard, R.S.; Bernstein, W.B.; Marovich, M.A.; Polhemus, M.E.; Yoon, I.K.; Hummer, K.A.; Gasser, R.A., Jr.; Oster, C.N.; Benson, P.M. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl. Trop. Dis., 2010, 4(3), e628.
309. Prasad, N.; Ghiya, B.C.; Bumb, R.A.; Kaushal, H.; Saboskar, A.A.; Lezama-Davila, C.M.; Salotra, P.; Satoskar, A.R. Heat, Oriental sore, and HIV. Lancet, 2011, 377(9765), 610.
310. Chen, M.; Christensen, S.B.; Theander, T.G.; Kharazmi, A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob. Agents Chemother., 1994, 38(6), 1339-1344. (Pubitemid 24170717)
311. Torres-Santos, E.C.; Rodrigues, J.M., Jr.; Moreira, D.L.; Kaplan, M.A.; Rossi-Bergmann, B. Improvement of in vitro and in vivo antileishmanial activities of 2', 6'-dihydroxy-4'-methoxychalcone by entrapment in poly(D,Llactide) nanoparticles. Antimicrob. Agents Chemother., 1999, 43(7), 1776-1778. (Pubitemid 29331268)
312. Alves, L.V.; Temporal, R.M.; Cysne-Finkelstein, L.; Leon, L.L. Efficacy of a diarylheptanoid derivative against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz, 2003, 98(4), 553-555. (Pubitemid 38019622)
313. Barata, L.E.; Santos, L.S.; Ferri, P.H.; Phillipson, J.D.; Paine, A.; Croft, S.L. Anti-leishmanial activity of neolignans from Virola species and synthetic analogues. Phytochemistry, 2000, 55(6), 589-595.
314. Fournet, A.; Ferreira, M.E.; Rojas de Arias, A.; Torres de Ortiz, S.; Inchausti, A.; Yaluff, G.; Quilhot, W.; Fernandez, E.; Hidalgo, M.E. Activity of compounds isolated from Chilean lichens against experimental cutaneous leishmaniasis. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol., 1997, 116(1), 51-54. (Pubitemid 27112816)
315. Nakayama, H.; Caballero, E.; Maldonado, M.; Torres, S.; E., S.; Sanabria, L.; Medarde, M.; Ferreira, M.-A.; de Arias, A.; San Feliciano, A. In vivo antileishmanial efficacy of combretastatin heteroanalogues. Rev. Latinoamer. Quim., 2009, 37(1), 56-64.
316. Fournet, A.; Ferreira, M.E.; Rojas De Arias, A.; Torres De Ortiz, S.; Fuentes, S.; Nakayama, H.; Schinini, A.; Hocquemiller, R. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother., 1996, 40(11), 2447-2451. (Pubitemid 26367623)
317. Chakrabarti, G.; Basu, A.; Manna, P.P.; Mahato, S.B.; Mandal, N.B.; Bandyopadhyay, S. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J. Antimicrob. Chemother., 1999, 43(3), 359-366. (Pubitemid 29121875)
318. Proulx, M.E.; Desormeaux, A.; Marquis, J.F.; Olivier, M.; Bergeron, M.G. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob. Agents Chemother., 2001, 45(9), 2623-2627. (Pubitemid 32801920)
319. Nakayama, H.; Loiseau, P.M.; Bories, C.; Torres de Ortiz, S.; Schinini, A.; Serna, E.; Rojas de Arias, A.; Fakhfakh, M.A.; Franck, X.; Figadere, B.; Hocquemiller, R.; Fournet, A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother., 2005, 49(12), 4950-4956. (Pubitemid 41778905)
320. Fournet, A.; Munoz, V.; Roblot, F.; Hocquemiller, R.; Cave, A.; Gantier, J.C. Antiprotozoal activity of dehydrozaluzanin C, a sesquiterpene lactone isolated from Munnozia maronii (asteraceae). Phytother. Res., 1993, 7(2), 111-115. (Pubitemid 23106460)
321. Ma, Y.; Lu, D.M.; Lu, X.J.; Liao, L.; Hu, X.S. Activity of dihydroartemisinin against Leishmania donovani both in vitro and in vivo. Chin. Med. J. (Engl.), 2004, 117(8), 1271-1273. (Pubitemid 39199942)
322. Arruda, D.C.; Miguel, D.C.; Yokoyama-Yasunaka, J.K.; Katzin, A.M.; Uliana, S.R. Inhibitory activity of limonene against Leishmania parasites in vitro and in vivo. Biomed. Pharmacother., 2009, 63(9), 643-649.
323. Yardley, V.; Khan, A.A.; Martin, M.B.; Slifer, T.R.; Araujo, F.G.; Moreno, S.N.; Docampo, R.; Croft, S.L.; Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother., 2002, 46(3), 929-931. (Pubitemid 34157693)
324. Miguel, D.C.; Yokoyama-Yasunaka, J.K.; Uliana, S.R. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl. Trop. Dis., 2008, 2(6), e249: Available from: http://www.plosntds.org/ article/info%3Adoi%2F10.1371%2Fjournal.pntd.00 00249
325. Miguel, D.C.; Zauli-Nascimento, R.C.; Yokoyama-Yasunaka, J.K.; Katz, S.; Barbieri, C.L.; Uliana, S.R. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother., 2009, 63(2), 365-368.
326. Karaji, A.G.; Hamzavi, Y. The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice. Exp. Parasitol., 2012, 130(1), 73-77.
327. Le Pape, P.; Abdala, H.; Pagniez, F.; Robert, J.M.; Le Baut, G. Activity of N-lutidinylcarboxamides against Leishmania donovani and L. braziliensis. Acta Parasitologica, 1999, 44(3), 156-159. (Pubitemid 29514336)
328. Al-Abdely, H.M.; Graybill, J.R.; Loebenberg, D.; Melby, P.C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother., 1999, 43(12), 2910-2914.
329. Bettiol, E.; Samanovic, M.; Murkin, A.S.; Raper, J.; Buckner, F.; Rodriguez, A. Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl. Trop. Dis., 2009, 3(2), e384: Available from: http://www.plosntds. org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.00 00384
330. Sharlow, E.R.; Close, D.; Shun, T.; Leimgruber, S.; Reed, R.; Mustata, G.; Wipf, P.; Johnson, J.; O'Neil, M.; Grogl, M.; Magill, A.J.; Lazo, J.S. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl. Trop. Dis., 2009, 3(11), e540: Available from: http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.00 00540
331. Walker, R.G.; Thomson, G.; Malone, K.; Nowicki, M.W.; Brown, E.; Blake, D.G.; Turner, N.J.; Walkinshaw, M.D.; Grant, K.M.; Mottram, J.C. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase. PLoS Negl. Trop. Dis., 2011, 5(4), e1033.
332. Cleghorn, L.A.; Woodland, A.; Collie, I.T.; Torrie, L.S.; Norcross, N.; Luksch, T.; Mpamhanga, C.; Walker, R.G.; Mottram, J.C.; Brenk, R.; Frearson, J.A.; Gilbert, I.H.; Wyatt, P.G. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem., 2011, 6(12), 2214-2224.
333. Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine. 2006, 1(3), 297-315.
334. Tiuman, T.S.; Santos, A.O.; Ueda-Nakamura, T.; Filho, B.P.; Nakamura, C.V. Recent advances in leishmaniasis treatment. Int. J. Infect. Dis., 2011, 15(8), e525-532.
335. Becquemont, L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics, 2009, 10(6), 961-969.
336. Davis, A.P.; Murphy, C.G.; Saraceni-Richards, C.A.; Rosenstein, M.C.; Wiegers, T.C.; Mattingly, C.J. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res., 2009, 37, D786-792.